Fresenius Kabi

Stimufend

Manufacturer:

Fresenius Kabi

Stimufend HCPCS:

Q5127

HCPCS Code Descriptor:

Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg

Category:

Q Code

Stimufend NDCs:

65219-0371-10

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Stimufend:

Stimufend is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Fresenius Kabi and administered via the Subcutaneous route of administration. The Q Code: Q5127 is aligned to the drug Stimufend.

Stimufend is used to prevent the lack of the white blood cells known as neutrophils. Stimufend is an artificial protein that aids in the production of neutrophils. This medication is manufactured by Fresenius Kabi USA and is biosimilar to the product Neulasta (J2506). The HCPCS code for Stimufend is Q5127, this HCPCS code was aligned to Stimufend in April 2023.

ACCESS PRICING AND MORE BY REGISTERING

Q5127 Added Date:

April 1, 2023

Q5127 Effective Date:

April 1, 2023

Q5127 Termination Date:

HCPCS Active

Stimufend billing and coding information can be found through Fresenius Kabi at the link below:
Stimufend patient assistance information can be found through KabiCare at the URL: https://stimufend.com/financial-assistance
Stimufend prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for Stimufend. Please check back in a few weeks.